Navigation Links
Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
Date:12/6/2007

Data Presentations Highlight Overall Survival Results of Vidaza(R) in

Higher-risk Myelodysplastic Syndromes (MDS), Thalidomide in Multiple

Myeloma

BOULDER, Colo., Dec. 6 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) reported today that data from 36 abstracts of studies investigating the company's marketed and pipeline hematology products will be presented at the American Society of Hematology's (ASH) 49th Annual Meeting and Exposition in Atlanta (December 8-11, 2007). These abstracts include summaries of data from studies of several key products in the company's commercial and development portfolio for a variety of indications, including Myelodysplastic Syndromes (MDS), acute myeloid leukemia (AML), multiple myeloma (MM), Hodgkin's lymphoma (HL), and two forms of non-Hodgkin's lymphoma (NHL).

"ASH promises to be a very exciting meeting for us, with a focus on the detailed presentation of data from the Vidaza overall survival study, which demonstrate an unprecedented survival benefit compared to conventional care regimens, as well as other compelling study data on Vidaza, Thalidomide and MGCD0103," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "The data from 36 abstracts, including 23 posters and 13 oral presentations, to be presented demonstrates the progress of our pipeline and we are very enthusiastic about our participation this year."

Studies presented at this year's ASH meeting will report the complete Phase 3 data set from a study demonstrating that Vidaza(R) (azacitidine for injection) provides a significant survival benefit beyond that provided by conventional care regimens for higher-risk MDS patients. rterly Report on Form 10-Q for the quarterly period ended September 30, 2007, its Annual Report on Form 10-K for the year ended December 31, 2006 and in Pharmion's other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and Pharmion undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise. Pharmion also disclaims any duty to comment upon or correct information that may be contained in reports published by the investment community.

Other data to be presented at the meeting include alternate dosing schedules of Vidaza and the use of Vidaza as a maintenance therapy for patients with higher-risk MDS and AML.

Additionally, data from a study of Vidaza in combination with MGCD0103 in MDS and AML will be presented at ASH, as will poster presentations featuring study results from two ongoing single-agent Phase 2 MGCD0103 trials, one in refractory/relapsed classical HL patients and the other in diffuse large B cell lymphoma and follicular lymphoma, two forms of NHL.

"The data on Pharmion's products being presented at ASH clearly demonstrate the importance of epigenetic therapy in the treatment of hematologic malignancies and Pharmion's leadership position in the field of epigenetics," said Andrew R. Allen, chief medical officer of Pharmion. "In particular, the data being presented confirming the clinical responses with Vidaza, MGCD0103 and their combination suggest a promising synergistic treatment approach using epigenetic therapies."

Pharmion's portfolio of epigenetic therapies includes three developmental programs: Vidaza and oral azacitidine, both DNA demethylating agents; MGCD0103, a HDAC inhibitor; and sirtuin inhibitors, Pharmion's newest epigenetic research program. Pharmion currently markets Vidaza, the parenteral formulation of Azacitidine, in the U.S. and several additional countries for the treatment of patients with MDS, and as previously mentioned the full data set from the Phase 3 study of Vidaza's effect on overall survival in higher-risk MDS patients will be presented at the meeting.

Data from a study evaluating the addition of Thalidomide to front-line melphalan/prednisone (MP) therapy in newly diagnosed elderly patients with multiple myeloma will be the subject of an oral presentation at ASH, where two oral presentations and three posters on Thalidomide studies will be presented.

The following data will be presented during the 49th Annual ASH Meeting and Exposition:

Vidaza(R)

Date / Time / Location: December 11, 2007; 7:30-9:00 a.m., Thomas B Murphy Ballroom 4, Georgia World Congress Center
Session: Myelodysplastic Syndromes: Advances in Therapeutic Options

-- Oral Session 7:30 a.m.: Azacitidine (AZA) Treatment Prolongs Overall

Survival (OS) in Higher-Risk MDS Patients Compared with Conventional

Care Regimens (CCR): Results of the AZA-001 Phase III Study (Abstract

#817).

-- Oral Session 7:45 a.m.: Maintenance Treatment with Azacytidine for

Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid

Leukemia in Complete Remission after Intensive Chemotherapy (Abstract

#818).

-- Oral Session 8:00 a.m.: Results of the Initial Treatment Phase of a

Study of Three Alternative Dosing Schedules of Azacitidine (Vidaza) in

Patients with Myelodysplastic Syndromes (MDS) (Abstract #819).

Date / Time / Location: December 8, 2007; Viewing 9:00 a.m.-7:30 p.m., Presentation 5:30 -7:30 p.m., Hall B4 of Georgia World Congress Center
Session: Acute Myeloid Leukemias: Therapy, Excluding Transplantation I

-- Poster Board No. 65-I: Report of a Phase I/II Study of 5-Azacitidine

and Cytarabine in Patients with Relapsed, Refractory Acute Myelogenous

Leukemia (Abstract #911).

Date / Time / Location: December 8, 2007; Viewing 9:00 a.m.-7:30 p.m., Presentation 5:30-7:30 p.m., Hall B4 of Georgia World Congress Center
Session: Myeloproliferative Syndromes: Biological

-- Poster Board No. 699-I: Hypermethylation of CXCR4 Promoter, and Its

Reactivation by Hypomethylating Agent, in CD34 + Cells from Primary

Myelofibrosis Patients (Abstract #1545).

Date / Time / Location: December 8, 2007; Viewing 9:00 a.m.-7:30 p.m., Presentation 5:30-7:30 p.m., Hall B4 of Georgia World Congress Center

Session: Myelodysplastic Syndromes: Clinical Studies, Including Transplantation
-- Poster Board No. 603-I: Outcomes of MDS Patients with Chromosome 7

Abnormalities Treated with 5-Azacytidine (Abstract #1449).

-- Poster Board No. 605-I: A Phase II Study of Intravenous Azacitidine

Alone in Patients with Myelodysplastic Syndromes (Abstract #1451).

-- Poster Board No. 606-I: Therapy of Myelodysplastic Syndrome (MDS)

with Azacitidine Given in Combination with Etanercept: A Phase II

Study (Abstract #1452).

-- Poster Board No. 612-I: Preliminary Results from a Phase I Study of

Revlimid (Lenalidomide) in Combination with Vidaza (Azacitidine) in

Patients with Advanced Myelodysplastic Syndromes (MDS) (Abstract

#1458).

Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Session: Acute Myeloid Leukemias: Therapy, Excluding Transplantation II

-- Poster Board No. 25-II: 5-Azacytidine Augments the Cytotoxicity of

Mylotarg toward AML Blasts In Vitro and In Vivo (Abstract # 1835).

-- Poster Board No 39-II: Treatment of AML with Azacytidine (AZA):

Current Results of the French ATU Program (Abstract #1849).

Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Session: Myelodysplastic Syndromes: Molecular Biology and Pathogenesis

-- Poster Board No 638-II: PI-PLCbeta1 Expression in Patients with

High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine

Treatment (Abstract #2448).

Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center

Session: Myelodysplastic Syndromes: Prognosis and Clinical Correlative Studies
-- Poster Board No. 656-II: FISH-Analyses of Circulating CD34+ Cells in

MDS-Patients -- A Suitable Method to Measure and Predict Response to

5-Azacytidine (Abstract #2466).

Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Session: Disordered Epigenetic Regulation in Hematologic Malignancy

-- Poster Board No. 312-II: DNA Methylation Analysis of 807 Genes in

Chronic Myeloid Leukemia and Acute Promyelocytic Leukemia (Abstract

#2122).

-- Poster Board No. 402-III: Up-Regulation of miR-195 Expression Leads

to Decreased Expression of Basic Fibroblast Growth Factor in CLL

Patients Treated with DNA Methylation Inhibitors (Abstract #3183).

Date / Time / Location: December 10, 2007; 1:30-3:00 p.m., Rooms B216-B217, Georgia World Congress Center
Session: Thalassemia: Pre-Clinical and Clinical Advances:

-- Oral Session 1:45 p.m.: Neither DNA Hypomethylation or Changes in the

Kinetics of Erythroid Differentiation Account for 5-Azacytidine's

Ability To Induce Human Fetal Hemoglobin (Abstract 572).

Date / Time / Location: December 10, 2007; 1:30-3:00 p.m., Rooms A411-A412, Georgia World Congress Center

Session: Acute Myeloid Leukemias: Therapy, Excluding Transplantation-Novel Therapies
-- Oral Session 2:45 p.m.: Phase I/II Study of MGCD0103, an Oral

Isotype-Selective Histone Deacetylase (HDAC) in Combination with

5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute

Myelogenous Leukemia (AML) (Abstract #444).

Date / Time / Location: December 10, 2007; Viewing 10:30 a.m.-7:00 p.m., Presentation 5:00-7:00 p.m., Hall B4 of Georgia World Congress Center

Session: Clinical Care: Transplantation Regimen Toxicities and Engraftment II
-- Poster Board No. 231-III: A Dose and Schedule Finding Study of

Maintenance Therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic

Hematopoietic Stem Cell Transplantation (HSCT) for High-Risk AML or

MDS (Abstract #3012).

-- Poster Board No. 232-III: Efficacy of Azacytidine (5-AC) Given as

Maintenance of Salvage Therapy for Patients with Acute Leukemia Post

Allogeneic Stem Cell Transplantation (HSCT) (Abstract #3013).

MGCD0103

Date / Time / Location: December 9, 2007; Viewing 6:00 p.m.-8:00 p.m., Presentation 6:00 p.m., Hall B4 of Georgia World Congress Center
Session: New Agents and Treatment Approaches in Non-Hodgkin Lymphoma

-- Poster Board No. 756-II: Isotype Selective HDAC Inhibitor MGCD0103

Decreases Serum TARC Concentrations and Produces Clinical Responses in

Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma

(Abstract #2566).

-- Poster Board No. 761-II: Treatment of Relapsed or Refractory Lymphoma

with the Oral Isotype-Selective Histone Deacetylase Inhibitor

MGCD0103: Interim Results from a Phase II Study (Abstract #2571).

Date / Time / Location: December 10, 2007; 1:30-3:00 p.m., Rooms A411-A412, Georgia World Congress Center

Session: Acute Myeloid Leukemias: Therapy, Excluding Transplantation-Novel Therapies
-- Oral Session 2:45 p.m.: Phase I/II Study of MGCD0103, an Oral

Isotype-Selective Histone Deacetylase (HDAC) in Combination with

5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute

Myelogenous Leukemia (AML) (Abstract #444).

Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Session: Disordered Epigenetic Regulation in Hematologic Malignancy

-- Poster Board No. 320-II: Analysis of Class I and II Histone

Deacetylase Fails To Identify a Human Leukemia Specific Expression

Profile (Abstract # 2130).

Thalidomide

Date / Time / Location: December 9, 2007; 4:30-6:00 p.m.; Rooms C303-C305, Georgia World Congress Center
Session: Myeloma: Firstline Phase III Trials in Multiple Myeloma

-- Oral Presentation -- 4:30 p.m.: Velcade-Thalidomide-Dexamethasone

(VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous

Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma

(Abstract #73).

-- Oral Presentation -- 5:00 p.m.: Melphalan-Prednisone-Thalidomide

(MP-T) Demonstrates a Significant Survival Advantage in Elderly

Patients .75 years with Multiple Myeloma Compared with

Melphalan-Prednisone (MP) in a Randomized, Double-blind,

Placebo-controlled Trial, IFM 01/01 (Abstract #75).

-- Oral Presentation -- 5:45 p.m.: Melphalan-Prednisone-Thalidomide to

Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled

Randomized Phase 3 Trial (Abstract #78).

Date / Time / Location: December 10, 2007; 7:30-9:00 a.m.; Rooms C303-C305, Georgia World Congress Center
Session: Myeloma: Frontline Therapy in Newly Diagnosed Multiple Myeloma

-- Oral Presentation -- 7:45 a.m.: A Phase II Study of Velcade,

Cyclophosphamide, Thalidomide and Dexamethasone as First-Line Therapy

for Multiple Myeloma (Abstract #188).

Date / Time / Location: December 10, 2007; 1:30-3:00 p.m.; Rooms C306-C308, Georgia World Congress Center

Session: Autologous Transplantation for Myeloma: Induction, Mobilization, and Biologic Correlates
-- Oral Presentation -- 2:00 p.m.: Incorporation of Thalidomide into

Up-Front Double Autologous Stem Cell Transplantation (ASCT) for

Multiple Myeloma Improves Outcome in Comparison with Double ASCT

without Thalidomide. Analysis of Baseline Factors Predictive of

Outcome (Abstract #447).

Date / Time / Location: December 10, 2007; 1:30-3:00 p.m.; Rooms C303-C305, Georgia World Congress Center

Session: Myeloma: Maintenance, Consolidation and Bone Disease in Multiple Myeloma
-- Oral Presentation -- 1:45 p.m.: Consolidation with Bortezomib,

Thalidomide, and Dexamethasone Induces Molecular Remissions in

Autografted Multiple Myeloma Patients (Abstract #530).

-- Oral Presentation -- 2:15 p.m.: Thalidomide-Dexamethasone vs

Interferon-Dexamethasone as Maintenance Treatment after ThaDD

induction for Multiple Myeloma: Final Analysis of a Prospective,

Randomized Study (Abstract #532).

Date / Time / Location: December 9, 2007; Viewing 9:00 a.m.-8:00 p.m., Presentation 6:00-8:00 p.m., Hall B4 of Georgia World Congress Center
Session: Myeloma: Relapsed and Refractory Multiple Myeloma

-- Poster Board No. 915-II: Longer Duration of Thalidomide Monotherapy

Results in Improved Outcome in Relapsed/refractory Multiple Myeloma

(Abstract #2725).

-- Poster Board No. 905-II: A Phase I/II Trial on Melphalan, Prednisone,

Thalidomide, and Defribotide Combination in Relapsed/Refractory

Multiple Myeloma Patients (Abstract #2715).

-- Poster Board No. 908-II: Prolonged Progression Free Survival Does Not

Relate to Quality of Response to Treatment with Thalidomide in

Patients with Relapsed Multiple Myeloma (Abstract #2718).

-- Poster Board No. 919-II: ThaDD-V Treatment for Patients with

Relapsed/Refractory Multiple Myeloma: A Feasibility/Activity Study

(Abstract #2729).

-- Poster Board No. 924-II: Effect of Thrombotic Events on Overall

Survival in Patients with Newly Diagnosed Myeloma: Analysis from a

Randomized Phase III Trial of Thalidomide plus Dexamethasone vs

Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00) (Abstract

#2734).

Date / Time / Location: December 10, 2007; Viewing 10:30 a.m.-7:00 p.m., Presentation 5:00-7:00 p.m., Hall B4 of Georgia World Congress Center
Session: Myeloma: Novel Therapies

-- Poster Board No 812-III: Thalidomide Combinations Improve Response

Rates; Results from the MRC IX Study (Abstract 3593).

About Pharmion

Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, including summary statements relating to the interim or preliminary results of clinical trials involving Vidaza, Thalidomide Pharmion, and MGCD0103. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the final results to differ significantly from the results summarized by such statements. Preliminary results may not be confirmed upon final analysis of the detailed results of a trial and additional information relating to the safety, efficacy or tolerability of Pharmion's products may be discovered upon further analysis of clinical trial data and upon review and analysis of additional clinical trial data from this or other clinical trials. Additional risks and uncertainties relating to Pharmion and its business can be found in the "Risk Factors" section of Pharmion's Qua
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: